REFERENCES
2. Bae J, Han E, Lee HW, et al. ; Fatty Liver Research Group of the Korean Diabetes Association. Metabolic dysfunction-associated steatotic liver disease in type 2 diabetes mellitus: a review and position statement of the fatty liver research group of the Korean Diabetes Association. Diabetes Metab J. 2024;48:1015-28.
3. Esposito M, Rimauro I, Frattolillo V, et al. MASLD in childhood as a multisystem health challenge beyond the liver. Trends Endocrinol Metab. 2025.
4. Li X, Zhou XD, Wu J, et al. Pediatric MASLD in China: epidemiology, screening, diagnosis, and management. Lancet Reg Health West Pac. 2025;64:101717.
5. Yadav AK, MacNeill JJ, Krylov A, et al. Sex- and age-associated factors drive the pathophysiology of MASLD. Hepatol Commun. 2024;8:e0523.
6. Mauvais-Jarvis F, Bairey Merz N, Barnes PJ, et al. Sex and gender: modifiers of health, disease, and medicine. Lancet. 2020;396:565-82.
7. Arnold AP, Klein SL, McCarthy MM, Mogil JS. Male-female comparisons are powerful in biomedical research - don’t abandon them. Nature. 2024;629:37-40.
8. Lonardo A, Suzuki A. Sex differences in alcohol-related liver disease, viral hepatitis, metabolic dysfunction-associated steatotic liver disease, and hepatocellular carcinoma. Explor Dig Dis. 2025;4:1005101.
9. Lonardo A, Trande P. Are there any sex differences in fatty liver? A study of glucose metabolism and body fat distribution. J Gastroenterol Hepatol. 2000;15:775-82.
10. Lonardo A, Nascimbeni F, Ballestri S, et al. Sex differences in nonalcoholic fatty liver disease: state of the art and identification of research gaps. Hepatology. 2019;70:1457-69.
11. World Health Organization. Gender and Health. Available from: https://www.who.int/health-topics/gender#tab=tab_1. [Last accessed on 29 January 2026].
12. Jamalinia M, Lonardo A, Weiskirchen R. Sex and gender differences in liver fibrosis: pathomechanisms and clinical outcomes. Fibrosis. 2024;2:10006.
13. Page A, Mann DA. Epigenetic regulation of liver fibrosis. Clin Res Hepatol Gastroenterol. 2015;39 Suppl 1:S64-8.
14. Feng G, Targher G, Byrne CD, et al. Global burden of metabolic dysfunction-associated steatotic liver disease, 2010 to 2021. JHEP Rep. 2025;7:101271.
15. Ballestri S, Nascimbeni F, Baldelli E, Marrazzo A, Romagnoli D, Lonardo A. NAFLD as a sexual dimorphic disease: role of gender and reproductive status in the development and progression of nonalcoholic fatty liver disease and inherent cardiovascular risk. Adv Ther. 2017;34:1291-326.
16. Burra P, Bizzaro D, Gonta A, et al. ; Special Interest Group Gender in Hepatology of the Italian Association for the Study of the Liver (AISF). Clinical impact of sexual dimorphism in non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Liver Int. 2021;41:1713-33.
17. Booijink R, Ramachandran P, Bansal R. Implications of innate immune sexual dimorphism for MASLD pathogenesis and treatment. Trends Pharmacol Sci. 2024;45:614-27.
18. Cherubini A, Della Torre S, Pelusi S, Valenti L. Sexual dimorphism of metabolic dysfunction-associated steatotic liver disease. Trends Mol Med. 2024;30:1126-36.
19. Penmetsa R, Kapil S, VanWagner LB. Sex and gender differences in metabolic dysfunction-associated liver disease. Indian J Gastroenterol. 2025.
20. Balakrishnan M, Patel P, Dunn-Valadez S, et al. Women have a lower risk of nonalcoholic fatty liver disease but a higher risk of progression vs men: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2021;19:61-71.e15.
21. Suzuki M, Kim HY, Reed MC, et al. Elevated homocysteine is associated with liver fibrosis in metabolic dysfunction-associated steatotic liver disease in a sex- and menopause-specific manner. Gastro Hep Adv. 2026;5:100800.
22. Shi Y, Zhang X, Wong T, et al. Sex differences in risk of adverse liver events in patients with cirrhosis. JAMA Netw Open. 2025;8:e2523674.
23. Acierno C, Barletta F, Caturano A, et al. Alcohol consumption and liver metabolism in the era of MASLD: integrating nutritional and pathophysiological insights. Nutrients. 2025;17:2229.
24. Lee C, Kim J, Han J, et al. Formyl peptide receptor 2 determines sex-specific differences in the progression of nonalcoholic fatty liver disease and steatohepatitis. Nat Commun. 2022;13:578.
25. Jamalinia M, Zare F, Mantovani A, Targher G, Lonardo A. Metabolic dysfunction-associated steatotic liver disease and sex-specific risk of fatal and non-fatal cardiovascular events: a meta-analysis. Diabetes Obes Metab. 2025;27:5171-81.
26. Meda C, Dolce A, Della Torre S. Metabolic dysfunction-associated steatotic liver disease across women’s reproductive lifespan and issues. Clin Mol Hepatol. 2025;31:327-32.
27. Taylor LC, Arthur G, de Carvalho Cruz M, Stec DE, Badmus OO. Contribution of sex differences to the development of cardiovascular disease in metabolic-associated steatotic liver disease (MASLD). Int J Transl Med (Basel). 2024;4:782-809.
28. Lonardo A, Suzuki A. Concise review: breastfeeding, lactation, and NAFLD. An updated view of cross-generational disease transmission and prevention. Metab Target Organ Damage. 2023;3:16.
29. Mantovani A, Petracca G, Beatrice G, et al. Non-alcoholic fatty liver disease and risk of incident chronic kidney disease: an updated meta-analysis. Gut. 2022;71:156-62.
30. Yan T, Zhang X, Wong T, Cheung R, Nguyen MH. Sex differences in adverse liver and nonliver outcomes in steatotic liver disease. JAMA Netw Open. 2024;7:e2448946.
31. Park H, Dawwas GK, Liu X, Nguyen MH. Nonalcoholic fatty liver disease increases risk of incident advanced chronic kidney disease: a propensity-matched cohort study. J Intern Med. 2019;286:711-22.
32. Sinn DH, Kang D, Jang HR, et al. Development of chronic kidney disease in patients with non-alcoholic fatty liver disease: a cohort study. J Hepatol. 2017;67:1274-80.
33. Kaps L, Labenz C, Galle PR, Weinmann-Menke J, Kostev K, Schattenberg JM. Non-alcoholic fatty liver disease increases the risk of incident chronic kidney disease. United European Gastroenterol J. 2020;8:942-8.
34. Arner P, Viguerie N, Massier L, et al. Sex differences in adipose insulin resistance are linked to obesity, lipolysis and insulin receptor substrate 1. Int J Obes (Lond). 2024;48:934-40.
35. Harvey BJ, Alvarez de la Rosa D. Sex differences in kidney health and disease. Nephron. 2025;149:77-103.
36. Lonardo A, Stefan N, Mantovani A. Widening research horizons on metabolic dysfunction-associated steatotic liver disease and cancer. Trends Endocrinol Metab. 2025;36:610-3.
37. Shi Y, Taherifard E, Saeed A, Saeed A. MASLD-Related HCC: A comprehensive review of the trends, pathophysiology, tumor microenvironment, surveillance, and treatment options. Curr Issues Mol Biol. 2024;46:5965-83.
38. Matz-Soja M, Berg T, Kietzmann T. Sex-related variations in liver homeostasis and disease: From zonation dynamics to clinical implications. J Hepatol. 2026;84:181-93.
39. Brie B, Ramirez MC, De Winne C, et al. Brain control of sexually dimorphic liver function and disease: the endocrine connection. Cell Mol Neurobiol. 2019;39:169-80.
40. Kasarinaite A, Sinton M, Saunders PTK, Hay DC. The influence of sex hormones in liver function and disease. Cells. 2023;12:1604.
41. Toniutto P, Shalaby S, Mameli L, et al. ; Special Interest Group Gender in Hepatology of the Italian Association for the Study of the Liver (AISF). Role of sex in liver tumor occurrence and clinical outcomes: a comprehensive review. Hepatology. 2024;79:1141-57.
42. Weiskirchen R, Lonardo A. The ovary-liver axis: molecular science and epidemiology. Int J Mol Sci. 2025;26:6382.
43. Xu L, Yuan Y, Che Z, et al. The Hepatoprotective and hepatotoxic roles of sex and sex-related hormones. Front Immunol. 2022;13:939631.
44. Xega V, Liu JL. Beyond reproduction: unraveling the impact of sex hormones on cardiometabolic health. Med Rev (2021). 2024;4:284-300.
45. Weiskirchen R, Lonardo A. Sex hormones and metabolic dysfunction-associated steatotic liver disease. Int J Mol Sci. 2025;26:9594.
46. Meda C, Benedusi V, Cherubini A, Valenti L, Maggi A, Della Torre S. Hepatic estrogen receptor alpha drives masculinization in post-menopausal women with metabolic dysfunction-associated steatotic liver disease. JHEP Rep. 2024;6:101143.
47. Lonardo A, Suzuki A. Sexual dimorphism of NAFLD in adults. Focus on clinical aspects and implications for practice and translational research. J Clin Med. 2020;9:1278.
48. Milani I, Parrotta ME, Colangeli L, et al. Sex differences in MASLD after age 50: presentation, diagnosis, and clinical implications. Biomedicines. 2025;13:2292.
49. Cherubini A, Ostadreza M, Jamialahmadi O, et al. ; EPIDEMIC Study Investigators. Author Correction: interaction between estrogen receptor-α and PNPLA3 p.I148M variant drives fatty liver disease susceptibility in women. Nat Med. 2024;30:1212.
50. Tripathi M, Yen PM, Singh BK. Estrogen-related receptor alpha: an under-appreciated potential target for the treatment of metabolic diseases. Int J Mol Sci. 2020;21:1645.
51. B'chir W, Dufour CR, Ouellet C, et al. Divergent role of estrogen-related receptor α in lipid- and fasting-induced hepatic steatosis in mice. Endocrinology. 2018;159:2153-64.
52. Chen CY, Li Y, Zeng N, et al. Inhibition of estrogen-related receptor α blocks liver steatosis and steatohepatitis and attenuates triglyceride biosynthesis. Am J Pathol. 2021;191:1240-54.
53. Weiskirchen R, Lonardo A. PNPLA3 as a driver of steatotic liver disease: navigating from pathobiology to the clinics via epidemiology. J Transl Genet Genom. 2024;8:355-77.
54. Wang Y, Hong S, Hudson H, et al. PNPLA3(148M) is a gain-of-function mutation that promotes hepatic steatosis by inhibiting ATGL-mediated triglyceride hydrolysis. J Hepatol. 2025;82:871-81.
55. Mahmood S, Morrice N, Thompson D, et al. Hydroxysteroid 17β-dehydrogenase 13 (Hsd17b13) knockdown attenuates liver steatosis in high-fat diet obese mice. Exp Physiol. 2025;110:1071-86.
56. Vilar-Gomez E, Pirola CJ, Sookoian S, Wilson LA, Liang T, Chalasani N. The protection conferred by HSD17B13 rs72613567 polymorphism on risk of steatohepatitis and fibrosis may be limited to selected subgroups of patients with NAFLD. Clin Transl Gastroenterol. 2021;12:e00400.
58. Ricken T, Werner D, Holzhütter HG, König M, Dahmen U, Dirsch O. Modeling function-perfusion behavior in liver lobules including tissue, blood, glucose, lactate and glycogen by use of a coupled two-scale PDE-ODE approach. Biomech Model Mechanobiol. 2015;14:515-36.
59. Lautt WW. Overview. In Granger DN, Granger J, Editors. Hepatic Circulation: Physiology and Pathophysiology. San Rafael (CA): Morgan & Claypool Life Sciences; 2009. pp. 7-18.
60. Kietzmann T. Metabolic zonation of the liver: the oxygen gradient revisited. Redox Biol. 2017;11:622-30.
61. Seubnooch P, Montani M, Dufour JF, Masoodi M. Spatial lipidomics reveals zone-specific hepatic lipid alteration and remodeling in metabolic dysfunction-associated steatohepatitis. J Lipid Res. 2024;65:100599.
62. Kim YS, Unno T, Kim BY, Park MS. Sex differences in gut microbiota. World J Mens Health. 2020;38:48-60.
63. Org E, Mehrabian M, Parks BW, et al. Sex differences and hormonal effects on gut microbiota composition in mice. Gut Microbes. 2016;7:313-22.
64. Mogna-Peláez P, Riezu-Boj JI, Milagro FI, et al. Sex-dependent gut microbiota features and functional signatures in metabolic disfunction-associated steatotic liver disease. Nutrients. 2024;16:4198.
65. Puhan S, Rekha SS, Sahu K, et al. Visiting MASLD through the lens of sex, immunity, and microbial interactions. Discov Med. 2025;2:236.
66. Pérez S, Rius-Pérez S. Macrophage polarization and reprogramming in acute inflammation: a redox perspective. Antioxidants (Basel). 2022;11:1394.
67. Zhou Z, Xu MJ, Cai Y, et al. Neutrophil-hepatic stellate cell interactions promote fibrosis in experimental steatohepatitis. Cell Mol Gastroenterol Hepatol. 2018;5:399-413.
68. Guo Z, Wu Q, Xie P, Wang J, Lv W. Immunomodulation in non-alcoholic fatty liver disease: exploring mechanisms and applications. Front Immunol. 2024;15:1336493.
69. Wang K, Li Y, Chen Y. Androgen excess: a hallmark of polycystic ovary syndrome. Front Endocrinol (Lausanne). 2023;14:1273542.
70. Lyu S, Yang J, Xin X, et al. Characteristics of serum bile acid profiles among individuals with metabolic dysfunction-associated steatotic liver disease. BMC Gastroenterol. 2025;25:334.
71. Wiese CB, Avetisyan R, Reue K. The impact of chromosomal sex on cardiometabolic health and disease. Trends Endocrinol Metab. 2023;34:652-65.
72. Twohig P, Li L, Danford D, Craft M, Yetman AT. Prevalence of hepatic steatosis and fibrosis in Turner syndrome: A prospective case-control study. Liver Int. 2024;44:1309-15.
73. Singh I, Noel G, Barker JM, et al. Hepatic abnormalities in youth with Turner syndrome. Liver Int. 2022;42:2237-46.
74. Davis SM, Nokoff NJ, Furniss A, et al. Population-based assessment of cardiometabolic-related diagnoses in youth with Klinefelter syndrome: a PEDSnet study. J Clin Endocrinol Metab. 2022;107:e1850-9.
75. Jamalinia M, Zare F, Mantovani A, Targher G, Lonardo A. Meta-analysis: liver disease burden and associated factors in turner syndrome. Aliment Pharmacol Ther. 2025. Epub 2025 Nov 14.
76. Marrone A, Allosso F, Caturano A, et al. Metabolic Dysfunction-associated steatotic liver disease in klinefelter syndrome: high prevalence uncovers an unmet need. J Clin Endocrinol Metab. 2025. dgaf479. Epub 2025 Aug 29.
77. Mameli C, Fiore G, Sangiorgio A, et al. Metabolic and nutritional aspects in paediatric patients with klinefelter syndrome: a narrative review. Nutrients. 2022;14:2107.
78. Chang S, Skakkebaek A, Davis SM, Gravholt CH. Morbidity in Klinefelter syndrome and the effect of testosterone treatment. Am J Med Genet C Semin Med Genet. 2020;184:344-55.
79. Wang J, Wu AH, Stanczyk FZ, et al. Associations between reproductive and hormone-related factors and risk of nonalcoholic fatty liver disease in a multiethnic population. Clin Gastroenterol Hepatol. 2021;19:1258-1266.e1.
80. Si G, Lv X, Ge Y, et al. Age at menarche and risk of non-alcoholic fatty liver disease: insights from the NHANES 2017-2020 and Mendelian randomization analyses. Exp Gerontol. 2025;204:112748.
81. Jaroenlapnopparat A, Charoenngam N, Ponvilawan B, Mariano M, Thongpiya J, Yingchoncharoen P. Menopause is associated with increased prevalence of nonalcoholic fatty liver disease: a systematic review and meta-analysis. Menopause. 2023;30:348-54.
82. Kim SE, Min JS, Lee S, Lee DY, Choi D. Different effects of menopausal hormone therapy on non-alcoholic fatty liver disease based on the route of estrogen administration. Sci Rep. 2023;13:15461.
83. Dong J, Dennis KMJH, Venkatakrishnan R, Hodson L, Tomlinson JW. The impact of estrogen deficiency on liver metabolism: implications for hormone replacement therapy. Endocr Rev. 2025;46:790-809.
84. Maldonado SS, Grab J, Wang CW, Huddleston H, Cedars M, Sarkar M. Polycystic ovary syndrome is associated with nonalcoholic steatohepatitis in women of reproductive age. Hepatol Commun. 2022;6:2634-9.
85. Liu D, Gao X, Pan XF, et al. The hepato-ovarian axis: genetic evidence for a causal association between non-alcoholic fatty liver disease and polycystic ovary syndrome. BMC Med. 2023;21:62.
86. Wu Z, Liang G, Zhang Y, Li R. Risk factors for metabolic dysfunction-associated steatotic liver disease in patients with polycystic ovary syndrome in east Asia: a review and meta-analysis. Endocr Pract. 2025;31:668-76.
87. El Jamaly H, Eslick GD, Weltman M. Systematic review with meta-analysis: non-alcoholic fatty liver disease and the association with pregnancy outcomes. Clin Mol Hepatol. 2022;28:52-66.
88. Froń A, Orczyk-Pawiłowicz M. Breastfeeding beyond six months: evidence of child health benefits. Nutrients. 2024;16:3891.
89. European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J Hepatol. 2024;81:492-542.
90. Diaz LA, Arab JP, Idalsoaga F, et al. Updated recommendations for the management of metabolic dysfunction-associated steatotic liver disease (MASLD) by the Latin American working group. Ann Hepatol. 2025;30:101903.
91. Younossi ZM, Zelber-Sagi S, Lazarus JV, et al. Global consensus recommendations for metabolic dysfunction-associated steatotic liver disease and steatohepatitis. Gastroenterology. 2025;169:1017-1032.e2.
92. Zargar AH, Bhansali A, Majumdar A, et al. Management of metabolic dysfunction-associated steatotic liver disease (MASLD)-an expert consensus statement from Indian diabetologists’ perspective. Diabetes Obes Metab. 2025;27 Suppl 4 Suppl:3-20.
93. Jamalinia M, Saeian S, Nikkhoo N, Nazerian A, Lankarani KB. Sex and gender differences in MASLD: pathophysiological mechanisms, clinical implications, and future directions. Metab Target Organ Damage. 2025;5:60.
94. Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, et al. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology. 2015;149. 367-78.e5; quiz e14-5.
95. Nascimbeni F, Ballestri S, Machado MV, et al. Clinical relevance of liver histopathology and different histological classifications of NASH in adults. Expert Rev Gastroenterol Hepatol. 2018;12:351-67.
96. Dileo E, Saba F, Parasiliti-Caprino M, Rosso C, Bugianesi E. Impact of sexual dimorphism on therapy response in patients with metabolic dysfunction-associated steatotic liver disease: from conventional and nutritional approaches to emerging therapies. Nutrients. 2025;17:477.
97. Bédard A, Corneau L, Lamarche B, Dodin S, Lemieux S. Sex-related differences in the effects of the mediterranean diet on glucose and insulin homeostasis. J Nutr Metab. 2014;2014:424130.
98. Leblanc V, Bégin C, Hudon AM, et al. Gender differences in the long-term effects of a nutritional intervention program promoting the Mediterranean diet: changes in dietary intakes, eating behaviors, anthropometric and metabolic variables. Nutr J. 2014;13:107.
99. D'Abbondanza M, Ministrini S, Pucci G, et al. Very low-carbohydrate ketogenic diet for the treatment of severe obesity and associated non-alcoholic fatty liver disease: the role of sex differences. Nutrients. 2020;12:2748.
100. Trouwborst I, Goossens GH, Astrup A, Saris WHM, Blaak EE. Sexual dimorphism in body weight loss, improvements in cardiometabolic risk factors and maintenance of beneficial effects 6 months after a low-calorie diet: results from the randomized controlled DiOGenes trial. Nutrients. 2021;13:1588.
101. Vitale M, Costabile G, Bergia RE, et al. The effects of Mediterranean diets with low or high glycemic index on plasma glucose and insulin profiles are different in adult men and women: data from MEDGI-Carb randomized clinical trial. Clin Nutr. 2023;42:2022-8.
102. Muscogiuri G, Verde L, Frias-Toral E, et al. Weight loss, changes in body composition and inflammatory status after a very low-energy ketogenic therapy (VLEKT): does gender matter? J Transl Med. 2024;22:949.
103. Zheng J, Zhou Z, Huang J, et al. Sugar rationing in the first 1000 days after conception and long-term risk of metabolic dysfunction-associated steatotic liver disease and major adverse liver outcomes: a natural experiment study. Clin Gastroenterol Hepatol. 2025:S1542-3565(25)00923.
104. Yang Y, He L, Han S, et al. Sex differences in the efficacy of glucagon-like peptide-1 receptor agonists for weight reduction: a systematic review and meta-analysis. J Diabetes. 2025;17:e70063.
105. van Oortmerssen JAE, Mulder JWCM, van der Bijl MF, Mijnster RJM, Kavousi M, Roeters van Lennep JE. ; IMPRESS consortium. Lipid lowering therapy utilization and lipid goal attainment in women. Curr Atheroscler Rep. 2025;27:29.
106. Weiskirchen R. Resmetirom and semaglutide in metabolic dysfunction-associated steatohepatitis (MASH): a comparative perspective. Explor Drug Sci. 2025;3:1008132.
107. Mahmoud M, Kawtharany H, Awali M, Mahmoud N, Mohamed I, Syn WK. The effects of testosterone replacement therapy in adult men with metabolic dysfunction-associated steatotic liver disease: a systematic review and meta-analysis. Clin Transl Gastroenterol. 2025;16:e00787.
108. LiverTox: clinical and research information on drug-induced liver injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012.
109. Bruno S, Maisonneuve P, Castellana P, et al. Incidence and risk factors for non-alcoholic steatohepatitis: prospective study of 5408 women enrolled in Italian tamoxifen chemoprevention trial. BMJ. 2005;330:932.
110. Braal CL, de Knegt RJ, Jager A, Koolen SLW, Mathijssen RHJ, Eechoute K. Tamoxifen use and potential effects on liver parenchyma: A long-term prospective transient elastographic evaluation. Hepatol Commun. 2022;6:2565-8.
111. Bessone F, Lucena MI, Roma MG, et al. Cyproterone acetate induces a wide spectrum of acute liver damage including corticosteroid-responsive hepatitis: report of 22 cases. Liver Int. 2016;36:302-10.
112. Yamada T, Tanaka S, Noda T, et al. Disproportionality analysis of flutamide- or bicalutamide-induced liver injury with and without steroids by using the Japanese Adverse Drug Event Report database. Int J Clin Pharm. 2025;47:128-35.
113. Nolan BJ, Cheung AS. Gender-affirming hormone therapy for transgender and gender-diverse adults in Australia. Intern Med J. 2024;54:1450-7.
114. Sluková D, Deischinger C, Just I, et al. The effects of gender-affirming hormone therapy on myocardial, hepatic, pancreatic lipid content, body fat distribution and other cardiometabolic risk factors: a magnetic resonance-based study in transgender individuals. J Clin Transl Endocrinol. 2025;39:100379.
115. Suvarna R, Shetty S, Pappachan JM. Efficacy and safety of Resmetirom, a selective thyroid hormone receptor-β agonist, in the treatment of metabolic dysfunction-associated steatotic liver disease (MASLD): a systematic review and meta-analysis. Sci Rep. 2024;14:19790.
116. Kantowski T, Schulze Zur Wiesch C, Aberle J, Lautenbach A. Obesity management: sex-specific considerations. Arch Gynecol Obstet. 2024;309:1745-52.
117. Resmirom Leaflet folded. Available from: https://getzpharma.com/wp-content/uploads/2025/04/Resmirom-Leaflet.pdf. [Last accessed on 29 January 2026].
